Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cells in vitro

Eur J Pharmacol. 2016 Mar 5:774:10-9. doi: 10.1016/j.ejphar.2015.11.039. Epub 2015 Dec 1.

Abstract

Furanodiene is a natural product isolated from Rhizoma curcumae, and exhibits broad-spectrum anti-cancer activities in vitro and in vivo. Our previous study proved that furanodiene could increase growth inhibition of steroidal agent in ERα-positive breast cancer cells, but whether furanodiene can influence ER status is not clear. In this study, we confirmed that furanodiene down-regulated the ERα protein expression level and inhibited E2-induced estrogen response element (ERE)-driven reporter plasmid activity in ERα-positive MCF-7 cells. Actually, ERα-knockdown cells were more sensitive than ERα positive cells to furanodiene on the cytotoxicity effect. So the anti-cancer effects of furanodiene and non-steroidal agent in breast cancer cells still requires further investigation. Our results showed that furanodiene exposure could enhance growth inhibitory effects of doxorubicin in ERα-negative MDA-MB-231 cells and ERα-low expression 4T1 cells. However, furanodiene did not increase the cytotoxicity of doxorubicin in ERα-positive breast cancer cells, non-tumorigenic breast epithelial cells, macrophage cells, hepatocytes cells, pheochromocytoma cells and cardiac myoblasts cells. Furanodiene enhances the anti-cancer effects of doxorubicin in ERα-negative breast cancer cells through suppressing cell viability via inducing apoptosis in mitochondria-caspases-dependent and reactive oxygen species-independent manners. These results indicate that furanodiene may be a promising and safety natural agent for cancer adjuvant therapy in the future.

Keywords: Apoptosis; Breast cancer; Combination; Doxorubicin; Doxorubicin (PubChem CID: 31703); Formaldehyde (PubChem CID: 712); Furanodiene; Furanodiene (PubChem CID: 636458); H2DCFDA (PubChem CID: 77718); Propidium iodide (PubChem CID: 104981); Tetradecanoylphorbol Acetate (PubChem CID: 27924); Thiazolyl blue (PubChem CID: 64965); tert-Butyl hydroperoxide (PubChem CID: 6410); z-VAD-fmk (PubChem CID: 5737); β-estrogen (PubChem CID: 5757).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Chloromethyl Ketones / pharmacology
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Breast / drug effects
  • Breast / pathology
  • Breast Neoplasms / pathology*
  • Doxorubicin / metabolism
  • Doxorubicin / pharmacology*
  • Drug Synergism
  • Epithelial Cells / drug effects
  • Estrogen Receptor alpha / metabolism*
  • Furans / pharmacology*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Hepatocytes / drug effects
  • Heterocyclic Compounds, 2-Ring / pharmacology*
  • Humans
  • MCF-7 Cells
  • Macrophages / drug effects
  • Myoblasts / drug effects
  • Pheochromocytoma / pathology
  • Reactive Oxygen Species / metabolism

Substances

  • Amino Acid Chloromethyl Ketones
  • Antineoplastic Agents
  • ESR1 protein, human
  • Estrogen Receptor alpha
  • Furans
  • Heterocyclic Compounds, 2-Ring
  • Reactive Oxygen Species
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • furanodiene
  • Doxorubicin